Align Technology, Inc. (ALGN)
POSITIVEFundamental
76
Precio
$158.46
Capitalización Bursátil
$11.34B
Parte 1 · Cuánto vale la empresa
Resumen
Align Technology makes Invisalign, a series of clear, custom-molded plastic trays that gradually straighten teeth as an alternative to metal braces, sold to orthodontists and general dentists who fit and monitor patients through the treatment. It also sells iTero intraoral scanners, which capture a 3D digital model of a patient's mouth used both to plan Invisalign treatment and, more broadly, for other dental and orthodontic work, plus the CAD/CAM software that runs the whole design and manufacturing process.
Cómo genera ingresos
Align earns Clear Aligner revenue per treatment case: a doctor orders a set of custom aligners, Align manufactures and ships them, and revenue is recognized as trays are delivered over the course of treatment. Systems and Services revenue comes from selling or leasing iTero scanners plus recurring CAD/CAM software and service fees. Because key aligner patents began expiring in 2017, pricing power now rests more on brand recognition, the doctor-training network and scanner ecosystem than on legal exclusivity.
Ingresos por segmento
Custom clear aligner trays for straightening teeth, sold per treatment case to orthodontists and general dentists worldwide.
iTero intraoral scanners plus the CAD/CAM software and services used to plan and manufacture both Invisalign and other dental work.
Ventaja competitiva
Marca · EstrechaInvisalign is the name patients ask for by default, built over two decades of marketing and a large trained network of certified doctors. But the aligner patents that once blocked competitors began expiring in 2017, and cheaper rivals plus direct-to-consumer and in-office 3D-printed alternatives have since chipped away at both volume growth and pricing.
Qué impulsa la demanda
Moderadamente cíclicoStraightening teeth is largely elective and often paid out of pocket or through limited dental insurance, so case volumes soften when consumers pull back discretionary spending. Growth also depends on expanding into new international markets and younger teen patients, both of which move independently of any single economic cycle but are still sensitive to household budgets.
Riesgos clave
- Patent expiry and low-cost competition — Key clear-aligner patents have expired in the US and abroad, letting lower-priced rivals and direct-to-consumer aligner services compete for the same patients and pressure the prices Align can charge.
- Discretionary consumer spending — Orthodontic treatment is often optional and expensive, so case starts slow when consumers are cautious about spending, even if their teeth alignment need has not changed.
- International and China exposure — A meaningful part of growth depends on international markets, including China, where local competitors, economic slowdown or regulatory change can reduce case volume independent of trends in the US.
- Intellectual property litigation — Align is involved in ongoing patent and other IP disputes with competitors and doctors; adverse rulings could restrict product features or require payments that reduce profitability.
Concentración de clientes
Align sells to hundreds of thousands of orthodontic and dental practices worldwide rather than a few large accounts, so no single customer represents a material share of revenue.
Los argumentos a favor
Buyers argue that Invisalign's brand recognition and trained doctor network still give it the largest share of a clear aligner market that keeps growing as more patients choose aligners over metal braces, with international expansion offering years of additional case growth.
Los argumentos en contra
Sellers fear that patent expiry has permanently opened the door to cheaper competitors, that elective treatment spending is exposed to consumer caution, and that growth increasingly depends on international markets where Align's brand advantage is weaker.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
Generated on 23 de agosto de 2026 with claude-opus-5 — shared with all users
Its Ormco unit sells the Spark clear aligner system to the same orthodontists Invisalign is sold to, competing case by case on aligner material, software and treatment planning.
Sells SureSmile clear aligners and Primescan intraoral scanners to the same dental practices, overlapping with both of Align's businesses at once.
Its ClearCorrect aligner brand competes for the same orthodontic and general-dentist customers worldwide, pushed through Straumann's large European implant and digital-dentistry sales network.
The largest clear aligner maker in China and now expanding into Europe, Latin America and Asia, taking aligner cases directly from Invisalign in the markets Align counts on for growth.
Its Dental Solutions arm sells Clarity aligners, brackets and bonding systems to orthodontists, competing for the same orthodontic case volume.
Its TRIOS intraoral scanners are the main alternative to Align's iTero scanners in dental practices, competing for the chairside digital-scanning workflow.
Balance y Liquidez
Ingresos
$4.14B
Últimos 12 meses (hasta 30/6/2026)
Beneficio Neto
$414M
Últimos 12 meses (hasta 30/6/2026)
Flujo de Caja Libre
$491M
Patrimonio Neto Total
$4.05B
Pasivo Total
$2.18B
Ratio de Liquidez
1.40
Cobertura de Intereses
-
Deuda/EBITDA
0.15
Beneficio Por Acción
Ingresos y Beneficio Neto
Flujo de Caja Libre
Desglose de Ingresos
Estado histórico
Márgenes en el tiempo
La deuda en el tiempo
Cuánto pesa la deuda
Cuadro de crecimiento
Crecimiento — Ingresos
Estimación de Valor Justo
Valor Justo
$122.06
Precio Actual
$158.46
Margen de Seguridad
-29.8%
Rango de Valor Justo
$79.34 - $164.78
Métodos de Estimación
Métricas de Valoración
Ratio P/E
27.81
ROE
10.1%
Ratio P/B
2.68
P/FCF
17.90
Margen Bruto
68.0%
ROIC
9.6%
Radar de Rentabilidad
Value Creation (Economic Moat)
ROIC
9.6%
WACC
13.5%
ROIC − WACC
-3.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Criterios de Análisis Fundamental
Superado (22)
- EPS shows upward trend
- EPS CAGR 9.65%
- Price CAGR 5.39%
- ROIC 9.6%
- Gross Margin 68.0%
- P/FCF 17.90
- P/B Ratio 2.68
- Debt/Equity ratio
- Operating Margin 13.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 10.1%
- Revenue Growth 5Y 10.3%
- Analyst Consensus 71% Buy
- Earnings Surprise avg 6.3%
- Earnings Quality (OCF/NI) 1.83
- Share Dilution -3.1%
- Piotroski F-Score 7/9
Fallido (3)
- Price below Graham Number
- DCF valuation (Overvalued)
- Net Margin Trend 10.0% vs 11.0%
No disponible (3)
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Solidez financiera fuerte
Calidad de los Beneficios
Alta calidad: beneficios respaldados por efectivo
Dilución de Acciones
Recomprando acciones. Favorable para el accionista
Gobernanza
Equipo Directivo
| Nombre | Cargo | Edad |
|---|---|---|
| Mr. Joseph M. Hogan | President, CEO & Director | 68 |
| Mr. John F. Morici | CFO & Executive VP of Global Finance | 58 |
| Mr. Zelko Relic | Executive VP & CTO | 60 |
| Ms. Shirley Stacy | Vice President of Corporate Communications & Investor Relations | - |
| Richardson Jaime Holte | Executive Vice President of Global Human Resources | - |
| Ms. Sreelakshmi Kolli | Executive VP and Chief Product & Digital Officer | 50 |
| Mr. Srini Kaza | Executive Vice President of Research & Development | - |
| Dr. Mitra Derakhshan | Executive VP, Chief Clinical Officer, Global Treatment Planning & Clinical Services | - |
| Mr. David Carr | Executive VP and MD of EMEA | - |
| Mr. Frank Quinn | Executive VP & MD of Americas Region | - |
Riesgo de Auditoría
1
Riesgo del Consejo
4
Riesgo de Compensación
9
Riesgo de Derechos del Accionista
7
Parte 2 · El precio y el momento de entrar
Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.
Latest News
Recent headlines for ALGN, sourced from Markets Gazette.
- 4/7/2026POSITIVEAlignment Stock Surges After 2.48% Medicare Rate Hike
Alignment Healthcare Inc. experienced a significant surge in its stock price following the Centers for Medicare & Medicaid Services (CMS) announcement of a 2.48% rate increase for 2027 Medicare Advantage and Part D programs. This favorable adjustment is expected to bolster the company's revenue streams and profitability, as these programs represent a substantial portion of Alignment Healthcare's business. Investors are reacting positively to the improved financial outlook, anticipating enhanced earnings and a stronger market position for the healthcare provider.
- 3/19/2026POSITIVEAlign Technology Shares Jump Following Report Of Large Elliott Position
Align Technology shares surged following news that activist investor Elliott Investment Management has taken a significant stake in the company. Elliott's involvement typically signals a push for strategic changes, often aimed at unlocking shareholder value. The move comes as Align Technology, the maker of Invisalign, faces challenges in its post-pandemic growth trajectory. Investors are likely interpreting this as a potential catalyst for operational improvements and a re-evaluation of the company's strategic direction, which could lead to enhanced financial performance.
- 3/19/2026NEUTRALElliott Builds Stake in Invisalign-Maker Align Technology
Hedge fund Elliott Investment Management has acquired a substantial stake in Align Technology Inc., the company renowned for its Invisalign clear aligners. This move by a prominent activist investor suggests potential for strategic changes or operational improvements within Align Technology. While the specific intentions of Elliott are not yet disclosed, such stake-building often precedes engagement with management to unlock shareholder value. Investors will be watching closely for any strategic shifts or performance enhancements that Elliott may advocate for, which could impact the company's future trajectory and stock performance.
via Markets Gazette